

## Review Article

# HCG variants, the growth factors which drive human malignancies

Laurence A Cole

USA hCG Reference Service, University of New Mexico, Albuquerque NM 87104, USA

Received August 25, 2011; accepted October 6, 2011; Epub November 20, 2011; Published January 1, 2012

**Abstract:** The term human chorionic gonadotropin (hCG) refers to a group of 5 molecules, each sharing the common amino acid sequence but each differing in meric structure and carbohydrate side chain structure. The 5 molecules are each produced by separate cells and each having separate biological functions. hCG and sulfated hCG are hormones produced by placental syncytiotrophoblast cells and pituitary gonadotrope cells. Hyperglycosylated hCG is an autocrine produced by placental cytotrophoblast cells. Hyperglycosylated hCG drives malignancy in placental cancers, and in testicular and ovarian germ cell malignancies. hCG $\beta$  and hyperglycosylated hCG $\beta$  are autocrines produce by most advanced malignancies. These molecules, particularly the malignancy promoters are presented in this review on hCG and cancer. hCG $\beta$  and hyperglycosylated hCG $\beta$  are critical to the growth and invasion, or malignancy of most advanced cancers. In many ways, while hCG may appear like a nothing, a hormone associated with pregnancy, it is not, and may be at the center of cancer research.

**Keywords:** Human chorionic gonadotropin (hCG), variants, growth factors, human malignancies, cancer


### Introduction

Human chorionic gonadotropin (hCG) is a glycoprotein hormone comprising an  $\alpha$ -subunit and  $\beta$ -subunit (**Figure 1**). hCG is considered the most acidic and most glycosylated glycoprotein (**Table 1**). The sugars form a key part of hCG's structure. The structure of the sugars on hCG are shown in **Figure 2**. **Figure 1** shows the 3 dimensional structure as predicted from X-ray crystallography [2].

Interestingly, the  $\beta$ -subunit (hCG $\beta$ ) has common evolutionary sequences with transforming growth factor  $\beta$  (TGF $\beta$ ) [3, 4]. Examination of the crystal structure of hCG [2] shows the presence on hCG $\beta$  of a cystine knot structure also common to TGF $\beta$  and other cytokines. This site of this cystine knot structure is shown in **Figure 1**. It comprises 4 overlapping  $\beta$ -subunit peptides,  $\beta$ 30-45,  $\beta$ 80-100,  $\beta$ 1-15 and  $\beta$ 50-65 linked by 3 disulfide bridges,  $\beta$ 34-88,  $\beta$ 9-57 and  $\beta$ 38-90. While the hormone hCG does not apparently expose these sequences and structures common to TGF $\beta$ , hCG variants can. As found, hy-

perglycosylated hCG, hCG $\beta$  and hyperglycosylated hCG $\beta$  all can seemingly antagonize a TGF $\beta$  receptor [5, 6]. As described later in this review, all these molecules are autocrine cancer promoters that seemingly act by antagonizing a TGF $\beta$  receptor on cancer cells.

Hyperglycosylated hCG is a second major form of hCG that seemingly functions as a TGF $\beta$  antagonist [6]. As such the amino acid sequence generates two independent dimeric molecules, hCG and hyperglycosylated hCG. While hCG functions as a hormone acting on the joint hCG/luteinizing hormone (LH) receptor, hyperglycosylated hCG functions as an autocrine as an apparent TGF $\beta$  antagonist and is produced by cytotrophoblast cells [6, 7]. hCG and hyperglycosylated hCG act together to control implantation of pregnancy and placental growth and function during pregnancy. Hyperglycosylated hCG is an over-glycosylated variant of hCG. As shown in **Table 1** and **Figure 2**, hyperglycosylated hCG has double size O-linked oligosaccharides and extra-large N-linked oligosaccharides. Considering the size of these oligosaccharides, they ac-



**Figure 1.** Crystal structure of deglycosylated regular hCG, as shown by Lathorn et al [2]. The unfolded  $\beta$ -subunit C-terminal peptide is added (missing in crystal structure). It is inferred that this structure is not folded since the sequence comprises primarily a polymer of proline and serine residues. The symbols N and O indicate the sites of attachment of N-linked and O-linked oligosaccharides. Residue  $\beta$ 48 and  $\beta$ 93 are indicated as the site of cleavage of the  $\beta$ -subunit. The symbol K indicates the site of the cystine knot structure. The  $\alpha$ -subunit is shown in grey, and  $\beta$ -subunit is shown in black.

count for 39% of the molecular weight (**Table 1**).

Hyperglycosylated hCG is the principal molecule produced in the first 3 weeks of pregnancy. At this time it controls implantation of pregnancy, and cytotrophoblast cell growth and invasion during the first trimester of pregnancy [8-14]. It is our understanding that antagonization of the cytotrophoblast cell TGF $\beta$  receptor leads to a cancer-like process, blockage of apoptosis, and secretion of invasive enzymes, metalloproteinases and collagenases, leading to growth and proteolytic invasion [15-25].


Hyperglycosylated hCG function for the length of pregnancy promoting root cytotrophoblast cell growth. The combination of hCG and hyperglycosylated hCG promote villous placental tissue growth, hyperglycosylated hCG promoting cytotrophoblast growth and hCG promoting the fusion of cytotrophoblast cells to syncytiotrophoblast cells. hCG also promoted umbilical artery angiogenesis and formation of the umbilical circulation. All these systems come together in formation of hemochorial placentation [26-34].

**Table 1.** Properties of 5 independent variants of hCG. Amino acid content, molecular weight and sugar contents determined from published structures as determined by Elliott et al. for hCG and hyperglycosylated hCG [90], Birken et al. for sulfated pituitary hCG [80] and Valmu et al. for hyperglycosylated hCG $\beta$  [91]. The molecular weight of common hCG dimer amino acid backbone is that as determined by Morgan et al. [122]. Molecular weight of N- and O-linked sugar side chains is added to these values. Isoelectric points are those published by Sutton et al. [92], and metabolic clearance rates are those established [1, 80].


Parameter	hCG	Sulfated hCG	Hyperglycosylated hCG	hCG $\beta$	Hyperglycosylated hCG $\beta$
Type of molecule	Hormone	Hormone	Autocrine	Autocrine	Autocrine
Total Molecular weight	37,180	36,150	42,800	23,300	27,600
Amino acids $\alpha$ -subunit	92	92	92	-	-
Amino acids $\beta$ -subunit	145	145	145	-	145
Peptide molecular weight	26,200	26,200	26,200	16,000	16,000
O-linked sugar units	4	4	4	4	4
N-linked sugar units	4	4	4	2	2
Molecular weight sugars	10,980	9,950	16,600	7,300	11,600
Percentage sugars	30%	28%	39%	31%	42%
Isoelectric point (pI), principal peak	3.5	Not known	3.2	Not known	3.5
Metabolic clearance rate	36 h	20 h	Not known	0.72 h	Not Known

N-linked oligosaccharides



hCG and hCGβ





O-linked oligosaccharides



Hyperglycosylated hCG and hyperglycosylated hCGβ



Sulfated hCG



**Figure 2.** The carbohydrate structure of hCG, hCGβ, hyperglycosylated hCG, hyperglycosylated hCGβ and sulfated hCG [80,90,91].

hCG and hyperglycosylated hCG evolved with humans [35, 36]. During their evolution came super-CG (chorionic gonadotropin) and super-hyperglycosylated CG two extremely potent growth factors that permitted hemochorial placentation to extend its efficiency multiple-fold in

humans [35, 36]. This was needed to permit the development of the human brain and humans [35, 36]. The human genome harbors genes to express super-hyperglycosylated CG and its derivatives, super-CGβ and super-hyperglycosylated CGβ. These are expressed in human can-

## HCG and cancer

**Table 2.** Parallelisms between placental implantation and invasion characteristics in primates, presence and sugar structure on chorionic gonadotropin (CG) or LH, and relative brain masses. Table summarizes published data [37-40,49,55].

Species	Implantation characteristics	Depth of Invasion	Sugar structures, acidity or pl	Brain mass (% of body weight)	First appearance
Humans	Hemochorial	1/3rd myometrium	CG, 8 oligosaccharides, pl 3.5	2.4%	0.1 million year ago
Advanced simian primates	Hemochorial	1/10th myometrium	CG, 6 oligosaccharides, pl 4.9	0.74%	20 million year ago
Early simian primates	Hemochorial	through decidua	CG, 5 oligosaccharides, pl 6.3	0.17%	37 million year ago
Prosimian primate	Epitheliochorial	no-invasion	No CG produced, LH0.07% produced, 3 oligosaccharides, pl 8.4		55 million years ago

**Table 3.** Use of serum free  $\beta$ -subunit (hCG $\beta$  plus hyperglycosylated hCG $\beta$ ) as a tumor marker for detection of malignancies. Averages are determined by combining total positive cases from multiple reports (89-79,100-113).

Malignancy	Number of Cases	Sensitivity (>3 fmol/ml)
Ovarian cancer	150	38%
Cervical cancer	60	37%
Endometrial cancer	55	33%
Vulvar	50	38%
Bladder cancer	170	35%
Lung cancer	243	18%
Colorectal cancer	436	17%
TOTAL	1164	Mean 30% detection

cers, and just as they permitted super-biology in human evolution, so will they permit unfortunately, super-biology in driving human cancers. This is the topic of this review.

Since this super-CG, super-hyperglycosylated CG driven process evolved to drive human evolution [35, 36]. It is important to understand human evolution first, before we consider human cancer, or a human evolution process gone haywire. The earliest primates, prosimian primates such as lemurs, had small brains, 0.07% of body weight (Table 2). This is because prosimian primates used inefficient non-invasive epitheliochorial placentation. With the evolution of the next level of primates, early

simian primates such as platyrrhine or the new world monkey, CG and hyperglycosylated CG first evolved, and along with these molecules came primitive hemochorial placentation [35, 36]. Hemochorial placentation, or fetal circulation filtration by syncytiotrophoblast cell surrounded by maternal blood, is much more efficient.

In 1980 Fiddes and Goodman [37], examined the DNA sequence for the  $\beta$ -subunits of CG and LH in humans and primates, and showed that the evolution of CG from LH occurred by a single deletion mutation in LH  $\beta$ -subunit DNA and read-through into the 3'-untranslated region in early simian primates. In 2002 Maston and Ruvolo

## HCG and cancer

**Table 4.** Use of urine  $\beta$ -subunit core fragment as a tumor marker for detection of malignancies. Data from multiple reports (89-79,100-113).

Malignancy	Number of cases	Sensitivity (>3 fmol/ml)
Ovarian cancer	207	66%
Cervical cancer	410	48%
Endometrial cancer	157	47%
Pancreatic cancer	29	55%
Bladder cancer	102	48%
Lung cancer	122	24%
TOTAL	1027	Mean 48% detection

[38], investigated the DNA sequences of the  $\beta$ -subunit of CG in 14 primates and showed that the genes to make CG and its variants were not present in prosimians or primitive primates (example: Lemur), but evolved by the indicated deletion mutation with the early simian primates (platyrrhine or new world monkey). The first or early simian primates CG and hyperglycosylated CG molecules had just 3 N-linked and 2 O-linked oligosaccharides (**Table 2**). These evolved with the species about 37 million year ago (**Table 2**). With the evolution of advanced simian primates about 20 million ago (examples: orangutan and chimpanzee), with further point mutations a form of CG and hyperglycosylated CG evolved that had 3 N-linked and 3 O-linked oligosaccharides (**Table 2**). With the evolution of humans, approximately 0.1 million year ago, and with further point mutations came the evolution of human CG and hyperglycosylated CG having 4 N-linked and 4 O-linked oligosaccharides. This increasing numbers of oligosaccharides and acidic sugars, 3 N-linked 2 O-linked, to 3 N-linked 3 O-linked and 4 N-linked 4 O-linked led to the evolution of a CG with an extreme acidity. Acidity ranged from pI 6.3 in early simians, to pI 4.8 in advanced simians and on to super-acidic pI 3.5 molecules in humans [35, 36, 38-40].

The metabolic clearance rate or circulating levels of CG were very much changed with acidity and evolution. As CG evolved with additional oligosaccharides containing sialic acid, it very much lengthened metabolic clearance rate of molecules and their effective bio-potency [38 41, 42]. As an example, at one extreme, regular

human CG has 4 O-linked and 4 N-linked oligosaccharides all terminating in sialic acid residues. These acidify hCG resulting in a molecule with a mean isoelectric point (pI) of 3.5, and a circulating half-life of 36 hours or 2160 minutes [1]. At the other extreme, is LH (pI 9.0 [43]), the molecule that CG evolved from, has just 3 N-linked oligosaccharides. The metabolic clearance half-life of LH is just 25 minutes [44], or 86 fold shorter than human CG. Human CG circulates for approximately 86 times longer than LH, raising the circulation concentration proportionately. A regression equation linking the number of oligosaccharides and the metabolic clearance rates them was formed. If clearance rate (minutes) half-life is CR and number of oligosaccharides is #O then  $CR = (2.4^{#O} \times 1.9)$ . Using this equation it was calculated that that the clearance rate half-life of early simian primate CG was approximately 2.5 hours and the clearance rate half-life of advanced simian primate CG was approximately 6 hours.

The size of the brain in mammals is directly related to the combination of body mass and the metabolic support of the developing progeny [45]. The larger brain size, seen in advanced primates and humans, correlates with disproportionately large energy demands by the developing fetuses [45-51]. Numerous studies support the concept that advanced primates, and to a greater extent humans, had to develop more efficient or super efficient placentation mechanisms to support the increasing nutritional demands of their embryonic brain (**Table 2**) [39, 40, 45-55].

The prosimian primate had an average size mammalian brain, 0.07% of body mass (**Table 2**). In this species, epitheliochorial placentation was sufficient. Hemochorial placentation started with the evolution of CG in early simian primate. It was only with the appearance of CG and hyperglycosylated CG in early simian primates, that the signals to implant placentas inside the uterus [8, 9, 12-14], and the signals to generate villous placenta [36, 36], to promote angiogenesis of uterine vasculature [29-32] and development of the umbilical cord [33, 34] that hemochorial placentation happened [35]. Hemochorial placentation was primitive in early simian primates, implanting only through the depth of the decidua, leading to a larger brain 0.17% of body mass (**Table 2**). It was with evolution and the development of more-acidic more-potent CG and hyperglycosylated CG that hemochorial placentation went deeper to 1/10<sup>th</sup> myometrial depth in advance simian primates (**Table 2**). This supported the development of a much larger brain, 0.74% of body mass (**Table 2**).

With the evolution of humans and the multiple mutations needed to produce their super-CG with 2 additional oligosaccharides, hemochorial placentation went to the extreme. CG jumped in acidity from metabolic clearance rate half-life of 360 to 2160 minutes. With this hemochorial placentation went deeper to 1/3<sup>rd</sup> the thickness of the myometrium (**Table 2**). Hemochorial placentation reached the efficiency needed to support a human brain, 2.4% of body mass.

Nutrition transfer and placentation were taken to the extreme in the humans. Human CG has a circulating half-time of 2160 minutes. This leads to invasion to one third the thickness of the myometrium and to the super-efficient placentation that is needed to support the nutritional transfer necessary for a brain of 2.4% body mass or 3 fold greater than that of advanced simians [46, 48, 49, 55]. Considering the relationship between regular CG, hyperglycosylated CG and hemochorial placentation, and between advancing acidity of CG and advancing invasion and angiogenesis, it would not be unreasonable to claim that the evolution of CG in early simians started primates on the evolution path to advanced brains, or is at the root of human evolution [35, 36].

It is with these evolution stories that super-CG

and super-hyperglycosylated CG or hCG and hyperglycosylated hCG were created, and this cancer story starts. Two potent growth promoters, normally reserved for evolution, and for pregnancy [35, 36]. Human cancers use hyperglycosylated hCG and its free subunit variants to drive the most efficient possible malignancy. It is at this point that this review starts.

### **HCG, one name shared by five independent molecules**

Research in the last 10 years has shown that the molecule generally called human chorionic gonadotropin (hCG) is not one independent molecule, but rather is 5 separate molecules with independent functions. The five separate forms of hCG all share a common amino acid backbone, thus have a common name. They vary greatly, however, in carbohydrate side chain structure and meric structure (**Table 1**).

hCG is a hormone made by placental syncytiotrophoblast cells [7]. hCG comprises a 92 amino acid  $\alpha$ -subunit and a 145 amino acid  $\beta$ -subunit. The  $\beta$ -subunit of hCG, while structurally similar to the  $\beta$ -subunit of LH, differentiates hCG from other glycoprotein hormones. hCG, like LH, is a hormone, and binds a common hCG/LH hormone receptor.

For the first 3 weeks of pregnancy, hCG promotes production of progesterone by ovarian corpus luteal cells [56-58]. Multiple research groups have shown that hCG also functions during pregnancy to promote angiogenesis in the uterine vasculature [29-32]. This insures maximal blood supply to the invading placenta, an important function during pregnancy. While hyperglycosylated hCG may promote cytotrophoblast cell growth during pregnancy [6, 9-14], hCG promotes the fusion of cells and their differentiation to syncytiotrophoblast cells [28]. It is the combination of these two processes that leads to villous trophoblast tissue formation and hemochorial placentation in pregnancy [35, 36]. Multiple groups show that hCG promotes an anti-macrophage inhibitory factor or a macrophage migration inhibitory factor that prevents destruction of the foreign fetoplacental by the mother's tissue during pregnancy [59, 60]. Other groups have shown that hCG also controls uterine growth during pregnancy [61, 62], and yet other groups have shown that hCG also relaxes myometrial contractions during pregnancy [63, 64].

It has been shown that hCG also control umbilical cord growth and circulation and development during pregnancy [33, 34]. New research is finding receptors in fetal organs and a further role for hCG in fetal growth during pregnancy [65, 66].

The structure of the N-linked and O-linked oligosaccharide side chains attached to the hormone hCG are shown in **Figure 2**. The three dimensional structure of hCG dimer was shown by Laphorn and colleagues (**Figure 1**) [2]. As shown, the  $\beta$ -subunit wraps itself around the  $\alpha$ -subunit (**Figure 1**). Hyperglycosylation of hCG subunits leads to incomplete folding, this leads to exposure of sequences otherwise hidden on hCG. These are the evolutionary TGF $\beta$  structures. Hyperglycosylated hCG is an autocrine, and not a hormone like hCG, it seemingly binds and antagonizes TGF $\beta$  receptors on the cytotrophoblast cells that make hyperglycosylated hCG [6, 8-26]. This is part of the process of pregnancy implantation. Hyperglycosylated hCG promotes blockage of apoptosis in these cells, and production of collagenases and metalloproteinases needed for invasion in the implantation process [8-26]. Hyperglycosylated hCG also promotes cytotrophoblast cells or placental growth during the length of pregnancy [11-14].

Hyperglycosylated hCG drives invasion as occurs in the fastest growing human malignancy, choriocarcinoma. Classically, a women may have a normal pregnancy, and deliver with just a few cytotrophoblast cell remaining at the implantation site. Transformation may occur in one of these remaining cells. Just 6 to 10 weeks later, the new mother may show at an emergency room with difficulty breathing and seizures, due to choriocarcinoma spreading to her lungs, and in her brain. This is choriocarcinoma, a malignancy totally driven by hyperglycosylated hCG and seemingly by the TGF $\beta$  antagonism process normally reserved for pregnancy implantation [6, 9, 11, 27, 67, 68].

Choriocarcinoma is not the only malignancy that produces hyperglycosylated hCG, and uses hyperglycosylated hCG to drive its malignancy. Testicular and ovarian germ cell malignancies take on a cytotrophoblast histology and are driven by hyperglycosylated hCG [9, 27]. These are the only malignancies that misuse this evolution growth factor to drive their malignancy, hyperglycosylated hCG. As we now understand,

all other malignancies use a similar TGF $\beta$  antagonism pathway when they can become advanced and can reach a state of differentiation whereby they express an hCG $\beta$  gene [69-79]. These cancer cells seemingly lack the ability to combine hCG subunits and just secrete hCG $\beta$  or hyperglycosylated hCG $\beta$ . Both of these molecules can antagonize the TGF $\beta$  receptor and promote malignancy [5, 6]. As now demonstrated, all advanced cancers are directly promoted to grow, invade and metastasize by an autocrine hCG $\beta$  or hyperglycosylated hCG $\beta$  [69-79]. Actions include inhibition of apoptosis in cancer cells and promotion of invasion proteases by cancer cells [41-48]. As demonstrated, recently, hyperglycosylated hCG, hCG $\beta$  and hyperglycosylated hCG $\beta$  are inter-changeable promoters, that all can promote choriocarcinoma or other advanced malignancies [6].

A fifth or final variant of hCG is made by pituitary gonadotrope cells during the menstrual cycle [80-83]. This is the sulfated variant of hCG with sulfated oligosaccharides as shown in **Table 1** and **Figure 2** [80]. Research by Odell and Griffin [81, 82] using an ultrasensitive hCG assay shows that sulfated hCG is produced during the length of the menstrual cycle, following the secretion pattern of LH. hCG and LH bind a common receptor. Research in Cole's laboratory shows that sulfated hCG production in 277 menstrual cycles at the time of the LH peak averages  $1.54 \pm 0.90$  mIU/ml [83]. It appears that sulfated hCG matches LH function in promoting androstenedione production by theca cells, progesterone production by corpus luteal cells and in enhancing ovulation.

### Choriocarcinoma and germ cell malignancies

Choriocarcinoma is a gestational trophoblastic disease, residing at the interface of obstetrics and oncology. Transformation in choriocarcinoma cases seemingly involves blockage of cytotrophoblast cells from fusing to form syncytiotrophoblast cells [9, 11, 27, 67, 68]. Cytotrophoblast cells are the site of hyperglycosylated hCG production, the driving force behind choriocarcinoma [9, 11].

The big question is what is the best tumor marker? Only one set of tumor markers fit this criterion, total hCG and hyperglycosylated hCG [67, 84-87]. Both of these tumor markers are 100% sensitive for choriocarcinoma. This is be-



cause choriocarcinoma cannot exist without hyperglycosylated hCG, as measured as hyperglycosylated hCG or total hCG immunoassays. No other tumor marker can make this claim. As demonstrated, when choriocarcinoma cells are grown in a nude mouse, they grow very rapidly. When an antibody is given to bind hyperglycosylated hCG, all growth completely stops [9, 11]. Similarly, when nude mice are administered choriocarcinoma cells in which the hCG subunit genes are blocked with anti-sense cDNA, all growth ceases [88, 89]. It is concluded that choriocarcinoma cannot exist without hyperglycosylated hCG.

The USA hCG Reference Service uses the B152 antibody hyperglycosylated hCG assay. This test detects hyperglycosylated hCG and its free  $\beta$ -subunit, hyperglycosylated hCG $\beta$  [90]. In the USA hCG Reference Service experience this tumor marker detects 100% of choriocarcinoma, persistent hydatidiform mole, testicular germ cell malignancy and ovarian germ cell malignancy cases. This test is diagnostic, it demonstrates malignant vs. quiescent or benign disease (<1% hyperglycosylated hCG) [85-87], in all these cancers. A company named Omnimmune Corp. (Houston, Texas) with its exclusive rights to B152 for cancer therapy, plans to humanize B152. This antibody possibly cures choriocarcinoma, persistent hydatidiform mole and testicular and ovarian germ cell malignancies

The first evidence that hyperglycosylated hCG functions in cancer through antagonizing a TGF $\beta$  receptor comes from the finding of evolutionary roots between hCG $\beta$  and TGF $\beta$  [3, 4], and from the finding of a 4 peptide cystine knot structure, common to hCG and TGF $\beta$  (and to nerve growth factor and platelet-derive growth factor) [2] (**Figure 1**). Multiple other articles show that the promotion of choriocarcinoma and pregnancy implantation (hyperglycosylated hCG), and metalloproteinase production, must be a TGF $\beta$ -mediated pathway [15-27]. Then there is the findings that the molecule which antagonized TGF $\beta$  in choriocarcinoma has the exact molecular size by polyacrylamide gel electrophoresis as hyperglycosylated hCG [26]. Finally, there is the demonstration that hyperglycosylated hCG, hCG $\beta$  and hyperglycosylated hCG $\beta$  are interchangeable, all competing with a TGF $\beta$  to bind a TGF $\beta$  receptor [5, 6]. It is inferred that hyperglycosylated hCG $\beta$ , hCG $\beta$  and

hyperglycosylated hCG act through similar mechanisms, TGF $\beta$  receptor antagonism, to control apoptosis, to control cell growth, and promote collagenases and metalloproteinases promoting invasion [5, 6, 15-26].

The story with choriocarcinoma and germ cell malignancies does not stop here. Choriocarcinoma is an important part of cancer history. It has always been at the root of major discoveries. It was at the root of discovery of chemotherapy as a cure for cancer. As was known, choriocarcinoma is an extremely fast growing malignancy. As Dr. Roy Hertz reasoned, why doesn't an inhibitor of cell division or DNA synthesis block choriocarcinoma cancer growth. As reasoned, methotrexate blocks the synthesis of the critical DNA nucleotide thymidine. Why doesn't methotrexate block choriocarcinoma growth? As shown by Dr. Hertz in the nineteen fifties, methotrexate makes an effective treatment of choriocarcinoma [93-95]. This discovery led to modern chemotherapy treatment for cancer.

Now here, we start again with choriocarcinoma showing that hyperglycosylated hCG drives invasion seemingly through a TGF antagonism mechanism. We go on to show in the next chapter that this mechanism applies to most advanced malignancies. We state again that B152 hyperglycosylated hCG antibody treatment seeming stops choriocarcinoma dead in its tracks, as shown in nude mouse studies [11, 88, 89]. Research is suggesting that hCG $\beta$  and hyperglycosylated hCG antibody treatment could become the future of all cancer treatment.

### Other malignancies

Here we consider all other malignancies, other than choriocarcinoma and germ cell malignancies. We consider all the common malignancies. Reports in the last 30 years show that most cancers, when advanced, produce an hCG $\beta$  immunoreactive substance [5, 69-79, 96-114].

As discovered in 1981 [96, 97], most other malignancies produce hCG $\beta$  or a large variant of hCG $\beta$ . In the following years, hundreds of research articles established that all human malignancies produced hCG $\beta$  or large variant of hCG $\beta$  [5, 69-79, 98-113]. hCG $\beta$  is detected in patient serum, or its degradation product  $\beta$ -core fragment is detected in urine. As shown recently by Valmu et al. [91], the large form of hCG $\beta$  is



actually hyperglycosylated hCG $\beta$ , a variant of hCG $\beta$  similar to the  $\beta$ -subunit of hyperglycosylated hCG. Why some cancers produce primarily hyperglycosylated hCG $\beta$  versus hCG $\beta$  is not known.

The literature shows that all advanced malignancies secrete hCG $\beta$  or hyperglycosylated hCG $\beta$  [98, 99], yet only a small proportion of malignancy cases, about 30%, have hCG $\beta$  or hyperglycosylated hCG $\beta$  in blood (**Table 3**), or their degradation product,  $\beta$ -core fragment present in urine of 48% of cancer cases (**Table 4**). This is because hCG $\beta$  and hyperglycosylated hCG $\beta$  are rapidly cleaved by the enzyme leukocyte elastase, produced by macrophages and leukocytes upon secretion. This enzyme first nicks or cleaves the molecules at  $\beta$ 47-48 upon secretion, and then cleaves this molecule's C-terminal, or major acidic component by cleavage at  $\beta$ 92-93 (**Figure 1**) [71, 115]. The resulting degradation products are rapidly cleared from the circulation by the liver and kidney, with circulating half lives of a few minutes versus 36 hour like hCG [71, 115]. This makes detection of the hCG $\beta$  or hyperglycosylated hCG $\beta$  in cancer cases very difficult, yielding a detection rate in blood of just 30%.

An accumulation of studies (**Tables 3 and 4**) shows that most malignancies produce this molecule [98, 99]. Urine  $\beta$ -core fragment is a useful tumor marker in gynecologic oncology, detecting 47% of endometrial, 48% of cervical and 66% of ovarian malignancies. Urine  $\beta$ -core fragment can be used as a simple three monthly screening test in women with familial ovarian cancer. Urine  $\beta$ -core fragment can be used as a wide spectrum cancer screening test. Yes, it detects 48% of all cancers, but a person positive in a  $\beta$ -core fragment assay can only then be screened with MRIs of the head and pelvis and chest CT to determine the site of malignancy.

Examination of the crystal structure of hCG [2], shows that the  $\beta$ -subunit has common evolutionary sequences with TGF $\beta$  [3, 4], and a cystine knot structure unique to hCG, TGF $\beta$ , platelet-derived growth factor and nerve growth factor. The site of this cystine knot structure is shown in **Figure 1**. As demonstrated [5], hCG $\beta$  antagonizes a TGF $\beta$  receptor site inhibiting apoptosis in the cancer cells, indicating that hCG $\beta$ , hyperglycosylated hCG and hyperglycosy-

lated hCG $\beta$  antagonize this receptor [5, 6, 69, 70]. As reported, hCG $\beta$  and hyperglycosylated hCG $\beta$  promote the production of collagenases and metalloproteinases, invasion proteases produced by cancer cells [69], leading to metastases.

As shown recently [6], cancers other than choriocarcinoma and germ cell malignancies produce hCG $\beta$  and hyperglycosylated hCG. Hyperglycosylated hCG, hCG $\beta$  and hyperglycosylated hCG $\beta$  are all interchangeable. Just as hCG $\beta$  can do hyperglycosylated hCG's job with choriocarcinoma, so can hyperglycosylated hCG do hCG $\beta$ 's job with other malignancies [6]. It appears that they all are interchangeable markers, all seemingly acting on a TGF $\beta$  receptor to antagonize it.

In recent years, hCG $\beta$  vaccines are being evaluated for patients with advanced cancers [116-121]. Initial clinical trials are extremely promising, showing a 2-fold extension of cancer survival [118-121]. The vaccine studies confirms the key role that hCG $\beta$ /hyperglycosylated hCG $\beta$  has in cancer metastasis and its action in all cancer cases.

It is my understanding that choriocarcinoma, persistent hydatidiform mole and germ cell malignancies are promoted by hyperglycosylated hCG in all stages. These are eutopic malignancies or malignancies driven by hyperglycosylated hCG. Hyperglycosylated hCG is seemingly the single cancer promoter, since cancer is brought to a complete halt in nude mice when hCG supply is blocked by antibody or DNA factors [11, 88, 89]. Other malignancies produce hCG $\beta$  and hyperglycosylated hCG $\beta$ . This is only produced in advanced disease [5, 69-79, 98-114]. It seems that the other or ectopic malignancies have to be advanced to differentiate tissues and to express ectopic hCG $\beta$ . From the time that hCG $\beta$  is ectopically expressed onwards hCG $\beta$  may be the principal driver of the malignancies. Based on the vaccine studies, it appears, as suggested [98, 99], that all malignancies may be controlled in advanced stages by hCG $\beta$  and/or hyperglycosylated hCG $\beta$ . It appears that once advanced malignancies start to express hCG $\beta$  and/or hyperglycosylated hCG $\beta$  that the malignancy may then be controlled by the TGF $\beta$  antagonism choriocarcinoma-like route by a molecule like hCG $\beta$ /hyperglycosylated hCG $\beta$ . It appears that hCG $\beta$ /hyperglycosylated hCG $\beta$  should be the target of

much cancer research, it is the future, the molecules that seemingly drive advanced malignancies.

### The future

In conclusion, it appears that hyperglycosylated hCG, hCG $\beta$  and hyperglycosylated hCG $\beta$  are an inter-related set of molecules [6]. That seemingly drive cancer through a TGF $\beta$  antagonism pathway [5, 6, 23, 25]. Choriocarcinoma and germ cell malignancies are all seemingly driven in early and advanced stages by this highly invasive pathway. In contrast, most other cancers are driven by alternative pathways until they become advanced and express the hCG $\beta$  gene. They seemingly adopt this viscous TGF $\beta$  antagonism pathway. This may be the key cancer physiology pathway.

This review presents research on cancers taking this pathway and promises for the future. Antibodies to hyperglycosylated hCG may seemingly cure choriocarcinoma and germ cell malignancies in the future, and vaccines to hCG $\beta$  and administered antibodies may significantly extend the lives of all advanced cancer patients. Vaccines may not work in some advanced stage cases, in patients with compromised immune systems. This is where administered antibodies may be most warranted.

In evolution, the molecule hyperglycosylated hCG was recruited to drive human evolution as an extreme growth factor. A growth factor that drove placental implantation deeper and growth to extremes. Unfortunately cancers take advantage of the availability of the extreme growth factors. It appears that the hCG $\beta$ /hyperglycosylated hCG $\beta$  TGF $\beta$  pathway may be the central pathway to treatment of all advanced cancers.

**Address correspondence to:** Dr. Laurence A Cole, USA hCG Reference Service, University of New Mexico, Albuquerque, NM 87131, USA Tel: 505-263-9635; E-mail: larry@hcglab.com

### References

- [1] Wehmann RE, Nisula BC. Metabolic and renal clearance rates of purified hCG. *J Clin Invest* 1981; 68: 184-94.
- [2] Laphorn AJ, Harris DC, Littlejohn A, Lustbader JW, Canfield RE, Machin KJ. Crystal structure of hCG. *Nature* 1994; 369: 455-461.
- [3] Laub M, Jennissen HP. Identification of the anthelix motif in the TGF- $\beta$  superfamily by molecular 3D-Rapid Prototyping. *Materialwissenschaft und Werkstofftechnik* 2003; 34: 1113-1119.
- [4] Lehnert SA, Akhurst RA. Embryonic expression pattern of TGF beta type-1 RNA suggests both paracrine and autocrine mechanisms of action. *Development* 1988; 104: 263-273.
- [5] Butler SA, Ikram MS, Mathieu S, Iles RK. The increase in bladder carcinoma cell population induced by the free beta subunit of hCG is a result of an anti-apoptosis effect and not cell proliferation. *Brit J Cancer* 2000; 82: 1553-1556.
- [6] Cole LA, Butler SA. Hyperglycosylated hCG, hCG $\beta$  and Hyperglycosylated hCG $\beta$ : Interchangeable Cancer Promoters. *Molec Cell Endocrinol* 2011; in press.
- [7] Kovalevskaya G, Genbacev O, Fisher SJ, Cacerre E, O'Connor JF. Trophoblast origin of hCG isoforms: cytotrophoblasts are the primary source of choriocarcinoma-like hCG. *Mol Cellul Endocrinol* 2002; 194: 147-155.
- [8] Sasaki Y, Ladner DG, Cole LA. Hyperglycosylated hCG the source of pregnancy failures. *Fertil Steril* 2008; 89: 1871-86.
- [9] Cole LA, Khanlian SA, Riley JM, Butler SA. Hyperglycosylated hCG (hCG-H) in Gestational Implantation, and in Choriocarcinoma and Testicular Germ Cell Malignancy Tumorigenesis. *J Reprod Med* 2006; 51: 919-929.
- [10] Cole LA. Biological function of hyperglycosylated hCG, in: Cole LA (ed), *HCG (hCG)*. Elsevier, Burlington MA 2010; pp: 49-65.
- [11] Cole LA, Dai D, Butler SA, Leslie KK, Kohorn EI. Gestational trophoblastic diseases: 1. Pathophysiology of hyperglycosylated hCG-regulated neoplasia. *Gynecol Oncol* 2006; 102: 144-149.
- [12] Guibourdenche J, Handschuh K, Tsatsaris V, Gerbaud MC, Legul F, Muller D, Evain-Brion D, Fournier T. Hyperglycosylated hCG is a marker of early human trophoblast invasion. *J Clin Endocrinol Metab* 2010; 95: E240-4.
- [13] Handschuh K, Guibourdenche J, Tsatsaris V, Guesnon M, Laurendeau I, Evain Brion D, Fournier T. HCG expression in human trophoblasts from early placenta, comparative study between villous and extravillous trophoblastic cells. *Placenta* 2007; 28: 175-84.
- [14] Handschuh K, Guibourdenche J, Tsatsari V, Guesnon M, Laurendeau I, Evain Brion D, Fournier T. HCG produced by the invasive trophoblast but not the villous trophoblast promotes cell invasion and is down-regulated by peroxisome proliferator-activated receptor- $\alpha$ . *Endocrinol* 2007; 148: 5011-19.
- [15] Schuster N, Kriegelstein K. Mechanisms of TGF- $\beta$ -mediated apoptosis. *Cell Tissue Res* 2002; 307: 1-14.
- [16] Kamijo T, Rajabi MR, Mizunuma H, Ibuki Y. Biochemical evidence for autocrine/paracrine

- regulation of apoptosis in cultured uterine epithelial cells during mouse embryo implantation in vitro. *Molec Human Reprod* 1998; 4: 990-8.
- [17] Pampferf S. Apoptosis in rodent peri-implantation embryos: differential susceptibility of inner cell mass and trophectoderm cell lineages-A review. *Placenta* 2000; 21: S3-S10.
- [18] Shooner C, Caron PC, Fréchette Frigon G, Leblanc V, Déry MC, Asselin E. TGF-beta expression during rat pregnancy and activity on decidual cell survival. *Reprod Biol Endocrinol* 2005; 3: 20.
- [19] Liu YX, Gao F, Wei P, Chen XL, Gao HJ, Zou RZ, Siao LJ, Xu FH, Feng Q, Liu K, Hu ZY. Involvement of molecules related to angiogenesis, proteolysis and apoptosis in implantation in rhesus monkey and mouse. *Contraception* 2005; 71: 249-62.
- [20] Knittel T, Mehde M, Kobold D, Saile B, Dinter C, Ramadori G. Expression patterns of matrix metalloproteinases and their inhibitors in parenchymal and non-parenchymal cells of rat liver regulation by TNF-alpha and TGF-beta1. *J Hepatol* 1999; 30: 48-60.
- [21] Murphy G, Reynolds JJ, Whitham SE, Docherty AJ, Angel P, Heath JK. Transforming growth factor beta modulates the expression of collagenase and metalloproteinase inhibitor. *Euro Molec Biol Org J* 1987; 6: 1899-1904.
- [22] Qureshi HY, Sylvester J, El Mabrouk M, Zafarullah M. TGF-beta-induced expression of tissue inhibitor of metalloproteinases-3 gene in chondrocytes is mediated by extracellular signal-regulated kinase pathway and Sp1 transcription factor. *J Cell Physiol* 2005; 203: 345-52.
- [23] Stetler Stevenson WG, Brown PD, Onisto M, Levy AT, Liotta LA. Tissue inhibitor of metalloproteinases-2 (TIMP-2) mRNA expression in tumor cell lines and human tumor tissues. *J Biol Chem* 1990; 265: 13933-13938.
- [24] Staun Ram E, Shaleu E. Human trophoblast function during the implantation process. *Reprod Biol Endocrinol* 2005; 3: 56-68.
- [25] Fisher SJ, Tian yi C, Li Z, Hartman L, Grahl K, Zhang GY, Tarpey J, Damsky CH. Adhesive and degradative properties of human placental cytotrophoblast cell in vitro. *J Cell Biol* 1989; 109: 891-902.
- [26] Khoo NK, Bechberger JF, Shepherd T, Bond SL, McCrae KR, Hamilton GS, Lala PK. SV40 Tag transformation of the normal invasive trophoblast results in a premalignant phenotype I Mechanisms responsible for hyperinvasiveness and resistance to anti-invasive action of TGFβ. *Intl J Cancer* 1998; 77: 429-39.
- [27] Cole LA. Hyperglycosylated hCG. *Placenta* 2007; 28: 977-986.
- [28] Shi QJ, Lei ZM, Rao CV, Lin J. Novel role of hCG in differentiation of human cytotrophoblasts. *Endocrinol* 1993; 132: 387-395.
- [29] Toth P, Li X, Rao CV, Lincoln SR, Sanfillipino JS, Spinnato JA, Yussman MA. Expression of functional hCG/human luteinizing hormone receptor gene in human uterine arteries. *J Clin Endocrinol Metab* 1994; 79: 307-315.
- [30] Zygmunt M, Herr F, Keller Schoenwetter S, Kunzi Rapp K, Munstedt K, Rao CV, Lang U, Preissner KT. Characterization of hCG as a novel angiogenic factor. *J Clin Endocrinol Metab* 2002; 87: 290-296.
- [31] Lei ZM, Reshef E, Rao CV. The expression of hCG/ luteinizing hormone receptors in human endometrial and myometrial blood vessels. *J Clin Endocrinol Metab* 1992; 75: 651-659.
- [32] Zygmunt M, Herr F, Keller Schoenwetter S, Kunzi Rapp K, Munstedt K, Rao CV, Lang U, Preissner KT. Characterization of hCG as a novel angiogenic factor. *J Clin Endocrinol Metab* 2002; 87: 290-5296.
- [33] Rao CV, Li X, Toth P, Lei ZM, Cook VD. Novel expression of functional hCG/luteinizing hormone receptor in human umbilical cords. *J Clin Endocrinol Metab* 1993; 77: 1706-1714.
- [34] Wasowicz G, Derecka K, Stepien A, Pelliniemi L, Doboszynska T, Gawronska B, Ziecik AJ. Evidence for the presence of luteinizing hormone-chorionic gonadotrophin receptors in the pig umbilical cord. *J Reprod Fertil* 1999; 117: 1-9.
- [35] Cole LA. hCG and hyperglycosylated hCG in the establishment and evolution of hemochorial placentation. *J Reprod Immunol* 2009; 82: 111-117.
- [36] Cole LA, Khanlian SA, Kohorn EI. Evolution of the Human Brain, Chorionic Gonadotropin and Hemochorial Implantation of the Placenta: Insights into Origins of Pregnancy Failures, Preeclampsia and Choriocarcinoma. *J Reprod Med* 2008; 53: 449-557.
- [37] Fiddes JC, Goodman HM. The cDNA for the β-subunit of hCG suggests evolution of a gene by readthrough into the 3'-untranslated region. *Nature* 1980; 286: 684-687.
- [38] Maston GA, Ruvolo M. Chorionic gonadotropin has a recent origin within primates and an evolutionary history of selection. *Mol Biol Evol* 2002; 19: 320-334.
- [39] Bambra CS. Purification and properties of baboon chorionic gonadotropin. *J Reprod Fertil* 1987; 19: 421-430.
- [40] Crawford RJ, Tegear GW, Niall HD. The nucleotide sequence of baboon chorionic gonadotropin β-subunit genes have diverged from the human. *Gene* 1986; 46: 161-169.
- [41] Cassels JW, Mann K, Blithe DL, Nisula RC, Wehmann RE. Reduced metabolic clearance of acidic variants of human choriogonadotropin from patients with testicular cancer. *Cancer* 1989; 64: 2313-2318.
- [42] Rosa C, Amr S, Birken S, Wehmann R, Nisula B. Effect of desialylation of hCG on its metabolic clearance rate in humans, *J Clin Endocri-*

- nol Metab 1984; 59: 1215-1219.
- [43] Keel BA, Grotjan HE. Characterization of rat pituitary luteinizing hormone charge microheterogeneity in male and female rats using chromatofocussing: effect of castration. *Endocrinol* 1985; 117: 354-360.
- [44] Valdhuis JD, Fraioli F, Rogol AD, Dufau ML. Metabolic clearance of biologically active luteinizing hormone in men. *J Clin Invest* 1986; 77: 1122-1128.
- [45] Martin RD. Relative brain size and basal metabolic rate in terrestrial vertebrates. *Nature* 1981; 293: 57-60.
- [46] Gibbons A. Solving the brain's energy crisis. *Science* 1998; 280: 1345-1347.
- [47] Robillard PY, Hulseley TC, Chaouat G. Preeclampsia and human reproduction. An essay of a long term reflection. *J Reprod Immunol* 2003; 59: 93-100.
- [48] Martin RD. Scaling of the mammalian barrier: the maternal energy hypothesis. *News Physiol Sci* 1996; 4: 149-154.
- [49] Cunnane SC, Herbige LS, Crawford MA. The importance of energy and nutrient supply in human brain evolution. *Nutr Health* 1993; 9: 19-35.
- [50] Martin RD. Human reproduction: a comparative background for medical hypotheses. *J Reprod Immunol* 2003; 59: 111-135.
- [51] Pjnenborg R. The placental bed. *Hypertens Pregn* 1996; 15: 7-23.
- [52] Kliman HJ. Uteroplacental blood flow. The story of decidualization, menstruation, and trophoblast invasion. *Am J Pathol* 2000; 157: 1759-1768.
- [53] Robillard PY, Chaline J, Chaouat G, Hulseley TC. Preeclampsia/eclampsia and the evolution of the human brain. *Current Anthropol* 2003; 44: 130-135.
- [54] Jauniaux E, Poston L, Burton GJ. Placental-related diseases of pregnancy: involvement of oxidative stress and implications in human evolution. *Human Reprod Updt* 2006; 12: 747-755.
- [55] Lockett WP. Comparative development and evolution of the placenta in primates. *Contrib Primatol* 1974; 3: 42-234.
- [56] Schmitt EJ, Barros CM, Fields PA M, Fields MJ, Diaz T, Kluge JM, Thatcher WW. A cellular and endocrine characterization of the original and induced corpus luteum after administration of a gonadotropin-releasing hormone agonist or hCG on day five of the estrous cycle. *J Anim Sci* 1996; 74: 1915-1929.
- [57] Richardson MC, Masson GM. Progesterone production by dispersed cells from human corpus luteum: stimulation by gonadotrophins and prostaglandin F2 $\alpha$ ; lack of response to adrenaline and isoprenaline. *J Endocrinol* 1980; 87: 247-254.
- [58] Hirose T. Experimentelle histologische studie zur genese corpus luteum. *Mitt Med Fakultd Univ ZU* 1919; 23: 63-70.
- [59] Akoum A, Metz CN, Morin M. Marked increase in macrophage migration inhibitory factor synthesis and secretion in human endometrial cells in response to hCG hormone. *J Clin Endocrinol Metab* 2005; 90: 2904-2910.
- [60] Wan H, Marjan A, Cheung VW, Leenen PJM, Khan NA, Benner R, Kiekens RCM. Chorionic gonadotropin can enhance innate immunity by stimulating macrophage function. *J Leukocyte Biol* 2007; 82: 926-933.
- [61] Reshef E, Lei ZM, Rao CV, Pridham DD, Chegini N, Luborsky JL. The presence of gonadotropin receptors in nonpregnant human uterus, human placenta, fetal membranes, and decidua. *J Clin Endocrinol Metab* 1990; 70: 421-430.
- [62] Zuo J, Lei ZM, Rao CV. Human myometrial chorionic gonadotropin/luteinizing hormone receptors in preterm and term deliveries. *J Clin Endocrinol Metab* 1994; 79: 907-911.
- [63] Eta E, Ambrus G, Rao V. Direct regulation of human myometrial contractions by hCG. *J Clin Endocrinol Metab* 1994; 79: 1582-1586.
- [64] Doheny HC, Houlihan DD, Ravikumar N, Smith TJ, Morrison JJ. Human chorionic gonadotropin relaxation of human pregnant myometrium and activation of the BKCa channel. *J Clin Endocrinol Metab* 2003; 88: 4310-4315.
- [65] Goldsmith PC, McGregor WG, Raymoure WJ, Kuhn RW, Jaffe RB. Cellular localization of chorionic gonadotropin in human fetal kidney and liver. *J Clin Endocrinol Metab* 1983; 57: 54-61.
- [66] Rao CV, Lei ZM. The past, present and future of nongonadal hCG/LH actions in reproductive biology and medicine. *Mol Cell Endocrinol* 2007; 269: 2-8.
- [67] Cole LA, Butler SA, Khanlian SA, Giddings A, Muller CY, Seckl MJ, Kohorn EI. Gestational trophoblastic diseases: 2. Hyperglycosylated hCG as a Reliable Marker of Active Neoplasia. *Gynecol Oncol* 2006; 102: 150-158.
- [68] Cole LA, Muller Y. hCG in the Management of Quiescent and Chemorefractory Gestational Trophoblastic Diseases. *Gynecol Oncol* 2010; 116: 3-9.
- [69] Butler SA, Iles RK. Biological function of the free  $\beta$ -subunit: expression and treatment target in cancer, in: Cole LA (ed), HCG (hCG). Elsevier, Burlington MA 2010; pp: 153-172.
- [70] Iles RK. Ectopic hCG $\beta$  expression by epithelial cancer: Malignant behavior metastasis and inhibition of tumor cell apoptosis. *Molec Cellul Endocrinol* 2007; 260: 264-270.
- [71] Cole LA, Birken S, Sutphen S, Hussa RO, Pattillo RA. Absence of the COOH-terminal peptide on ectopic hCG  $\beta$ -subunit (HCG- $\beta$ ). *Endocrinol* 1982; 110: 2198-2200.
- [72] Butler SA, Iles RK. Ectopic human chorionic gonadotrophin  $\beta$  secretion by epithelial tumors and human chorionic gonadotrophin  $\beta$

- induced apoptosis in Kaposi's sarcoma, is there a connection? *Clin Cancer Res* 2003; 9: 4666-4673.
- [73] Carter WB, Sekharem M, Coppola D. HCG induces apoptosis in breast cancer. *Breast Cancer Res Treatm* 2006; 100: S243-S244.
- [74] Bellet D, Lazar V, Bleche I, Paradis V, Giovangrandi Y, Paterliru P. Malignant transformation of nontrophoblastic cells in association with the expression of chorionic gonadotropin  $\beta$  genes normally transcribed in trophoblastic cells. *Cancer Res* 1997; 57: 516-523.
- [75] Cosgrove DE, Campain JA, Cox GS. Chorionic gonadotropin synthesis by human tumor cell lines: Examination of subunit accumulation steady-state levels of mRNA and gene structure. *Biochem Biophys Acta* 1989; 1007: 44-54.
- [76] Marcillac I, Cottu P, Theodore C, Lacombe MJ, Bellet D, Droz JP. Free hCG beta subunit as tumour marker in urothelial cancer. *Lancet* 1993; 341: 1354-1355.
- [77] Cole LA.  $\beta$ -core fragment ( $\beta$ -core UGP or UGF). *Tumor Marker Update* 1994; 6: 69-75.
- [78] Iles RK. Human chorionic gonadotrophin and its fragments as markers of prognosis in bladder cancer. *Tumor Marker Update* 1995; 7: 161-166.
- [79] Gillott DJ, Iles RK, Chard T. The effects of  $\beta$ -human chorionic gonadotrophin on the in vitro growth of bladder cancer cell lines. *Br J Cancer* 1996; 73: 323-326.
- [80] Birken S, Maydelman Y, Gawinowicz MA, Pound A, Liu Y, Hartree AS. Isolation and characterization of human pituitary chorionic gonadotropin. *Endocrinol* 1996; 137: 1402-11.
- [81] Odell WD, Griffin J. Pulsatile secretion of hCG in normal adults. *N Engl J Med* 1987; 317: 1688-91.
- [82] Odell WD, Griffin J. Pulsatile secretion of chorionic gonadotropin during the normal menstrual cycle. *J Clin Endocrinol Metab* 1989; 69: 528-32.
- [83] Cole LA, Ladner DG, Cole LA, Gutierrez JM. Production of hCG during the menstrual cycle. *J Reprod Med* 2009; 54: 245-250.
- [84] Hancock BW, Newlands ES, Berkowitz RS, Cole LA. Chapman and Hall. London UK 1997; pp: 1-502.
- [85] Cole LA, Laidler L, Muller C. USA hCG Reference Service, 10 year report. *Clin Biochem* 2010; 43: 1013-1022.
- [86] Cole LA, Muller Y. hCG in the Management of Quiescent and Chemorefractory Gestational Trophoblastic Diseases. *Gynecol Oncol* 2010; 116: 3-9.
- [87] Cole LA. Human Chorionic Gonadotropin and Associated Molecules. *Expert Rev Molec Diag* 2009; 9: 51-73.
- [88] Lei ZM, Taylor DD, Gercel Taylor C, Rao CV. HCG promotes tumorigenesis of choriocarcinoma JAR cells. *Troph Res* 1999; 13: 147-159.
- [89] Hamade AL, Nakabayashi K, Sato A, Kiyoshi K, Takamatsu Y, Laoag-Fernandez JB, Ohara N, Maruo T. Transfection of antisense chorionic gonadotropin  $\beta$  gene into choriocarcinoma cells suppresses the cell proliferation and induces apoptosis. *J Clin Endocrinol Metab* 2005; 90: 4873-4879.
- [90] Elliott MM, Kardana A, Lustbader JW, Cole LA. Carbohydrate and Peptide structure of the  $\alpha$ - and  $\beta$ -subunits of hCG from normal and aberrant pregnancy and choriocarcinoma. *Endocrine* 1997; 7: 15-32.
- [91] Valmu L, Alfthan H, Hotakainen K, Birken S, Stenman UH. Site-specific glycan analysis of hCG {beta}-subunit from malignancies and pregnancy by liquid chromatography - electrospray mass spectrometry. *Glycobiology* 2006; 16: 1207-1218.
- [92] Sutton JM. Charge variants in serum and urine hCG. *Clin Chem Acta* 2004; 341: 199-203.
- [93] Hertz R, Bergenstal DM, Lipsett MB, Price EB, Hilbish TF. Chemotherapy of choriocarcinoma and related trophoblastic tumors in women. *J Am Med Assoc* 1958; 18: 845-854.
- [94] Li MC, Hartz R, Bergenstal DM. Therapy of choriocarcinoma and related trophoblastic tumors with folic acid and purine antagonists. *New Engl J Med* 1958; 10: 66-74.
- [95] Hertz R, Li MC, Spencer DB. Effect of methotrexate therapy upon choriocarcinoma and chorioadenoma. *Proc Soc Exp Biol Med* 1956; 93: 361-366.
- [96] Cole LA, Hussa RO. Use of glycosidase digested hCG  $\beta$ -subunit to explain the partial binding of glycoprotein hormones to Con A. *Endocrinol* 1981; 109: 2276-2279.
- [97] Cole LA, Hussa RO, Rao CV. Discordant synthesis and secretion of hCG and subunits by cervical cancer cells. *Cancer Res* 1981; 41: 1615-1619.
- [98] Acevedo HF, Hartstock RJ. Metastatic phenotype correlates with high expression of membrane-associated complete  $\beta$ -hCG in vivo. *Cancer* 1996; 78: 2388-2399.
- [99] Regelson W. Have we found the "definitive cancer biomarker"? The diagnostic and therapeutic implications of hCG-beta statement as a key to malignancy. *Cancer* 1995; 76: 1299-1301.
- [100] Iles RK. Human chorionic gonadotrophin and its fragments as markers of prognosis in bladder cancer. *Tumor Marker Update* 1995; 7: 161-166.
- [101] Schwartz PE, Chambers JT, Taylor KJ, Cole LA, Makuch R. Urinary gonadotropin fragments. *Anticancer Res* 1993; 13: 1722-1725.
- [102] Muller C, Cole LA. The Quagmire of hCG and hCG Testing in Gynecologic Oncology. *Gynecol Oncol* 2009; 112: 663-672.
- [103] Rosen SW, Calvert I, Weintraub BD, Tseng JS, Rabson AS. Stimulation of N602'-dibutylryl

- cyclic adenosine 3':5'-monophosphate of ectopic production of the free beta subunit of chorionic gonadotropin by a human brain tumor cell line. *Cancer Res* 1980; 40: 4325-4328.
- [104] Cook AM, Huddart RA, Jay G, Norman A, Dearnaley DP, Horwich A. The utility of tumour markers in assessing the response to chemotherapy in advanced bladder cancer. *British Journal of Cancer* 2000; 82: 1952-1957.
- [105] Cole LA, Tanaka A, Kim GS, Park SY, Koh MW, Schwartz PE, Chambers JT, Nam JH. Beta-Core Fragment (beta-Core/UGF/UGP), a Tumor Marker: A 7-Year Report. *Gynecol Oncol* 1996; 60: 264-270.
- [106] Acevedo HF, Tong JY, Hartsock RJ. HCG-beta subunit gene statement in cultured human fetal and cancer cells of different types and origins. *Cancer* 1995; 76: 1467-75.
- [107] Nishimura R, Baba S, Hasegawa K, Kinugasa M, Okamura M, Kimura A, Ohtsu F, Takeuchi K. Characterization of immunoreactive hCG beta-subunit in cultured fluids of the cell lines derived from gynecologic malignant tumors. *Nippon Sanka Fujinka Gakkai Zasshi* 1990; 42: 1471-1476.
- [108] Bepler G, Jaques G, Oie HK, Gazdar AF. HCG and related glycoprotein hormones in lung cancer cell lines. *Cancer Lett* 1991; 58: 145-150.
- [109] Ozturk M, Bellet D, Isselbacher KJ, Wands J. Ectopic beta-hCG production by a human hepatoma cell line (FOCUS): isolation and immunochemical characterization. *Endocrinol* 1987; 120: 559-566.
- [110] Udagawa Y, Nozawa S, Chin K, Sakayori M, Mikami M, Ohta K, Tsukazaki K. Biological properties of two newly established cell lines (SKG- 3a,3b) from a human uterine cervical epidermoid carcinoma. *Nippon Sanka Fujinka Gakkai Zasshi* 1984; 36: 237-246.
- [111] Cole LA, Schwartz PE, Wong Y. Urinary gonadotropin fragments (UGF) in cancers of the female reproductive system: I Sensitivity and specificity comparison with other markers. *Gynecol Oncol* 1988; 31: 82-90.
- [112] Szturmowicz M, Slodkowska J, Zych J, Rudzinski P, Sakowicz A, Rowinska Zakrzewska E. Frequency and Clinical Significance of  $\beta$ -Subunit HCG Expression in Non-Small Cell Lung Cancer Patients. *Tumor Biol* 1999; 20: 99-104.
- [113] Kinugasa M, Nishimura R, Koizumi T, Morisue K, Higashida T, Natazuka T, Nakagawa T, Isobe T, Baba S, Hasegawa K. Combination assay of urinary beta-core fragment of hCG with serum tumor markers in gynecologic cancers. *Jpn J Cancer Res* 1995; 86: 783-789.
- [114] Ruddon RW, Norton SE. Use of biological markers in the diagnosis of cancers of unknown primary tumor. *Semin Oncol* 1993; 20: 251-260.
- [115] Cole LA, Kardana A, Andrade Gordon P, Gawinowicz MA, Morris JC, Bergert, ER, O'Connor J, Birken S. The Heterogeneity of hCG: III. The occurrence, biological and immunological activities of nicked hCG. *Endocrinology* 1991; 129: 1559-1567.
- [116] Delves PJ, Iles RK, Roitt IM, Lund T. Designing a new generation of anti-hCG vaccines for cancer therapy. *Molec Cellular Endocrinol* 2007; 260: 276-281.
- [117] Iversen PL, Mourich DV, Moulton HM. Monoclonal antibodies to two epitopes of  $\beta$ -hCG for the treatment of cancer. *Cur Opin Molec Therap* 2003; 5: 156-160.
- [118] Moulton HM, Yoshihara PH, Mason DH, Iversen PL, Triozzi PL. Active specific immunotherapy with  $\beta$ -hCG peptide vaccine in patients with metastatic colorectal cancer: Antibody response is associated with improved survival. *Clin Cancer Res* 2002; 8: 2044-2051.
- [119] Morse MA, Chapman R, Powderly J, Blackwell K, Keler T, Green J, Riggs R, He LZ, Ramakrishna V, Vitale L, Zhao B, Butler SA, Hobeika A, Osada T, Davis T, Clay T, Lyerly HK. Phase I Study Utilizing a Novel Antigen-Presenting Cell-Targeted Vaccine with Toll-like Receptor Stimulation to Induce Immunity to Self-antigens in Cancer Patients. *Clin Cancer Res* 2011; 17: 4844-4853.
- [120] He LZ, Ramakrishna V, Connolly JE, Wang XT, Smith P, Jones CL, Valkova Valchanova M, Arunakumari A, Tremi JF, Goldstein J, Wallace PK, Keler T, Endres MJ. A Novel Human Cancer Vaccine Elicits Cellular Responses to the Tumor-Associated Antigen, HCG  $\beta$ . *Clin Cancer Res* 2004; 10: 1920-1924.
- [121] Triozzi PL, Stevens VC. HCG as a target for cancer vaccines. *Oncol Rep* 1999; 6: 7-17.
- [122] Morgan FJ, Birken S, Canfield RE. The Amino Acid Sequence of HCG. *J Biol Chem* 1975; 250: 5247-5258.